Drug intelligence / Profile preview

Qinwei Jiaonang

Development stage: Unknown
Lead developer: Sichuan Academy of Chinese Medical Sciences
Administration: Oral

Overview

Qinwei Jiaonang is a traditional Chinese medicine (TCM) capsule developed by the Sichuan Academy of Chinese Medicine Sciences for the treatment of nonalcoholic steatohepatitis (NASH). It is specifically formulated for patients presenting with the TCM pattern of damp-heat accumulation. The drug is currently being evaluated in a randomized, double-blind, placebo-controlled Phase II clinical trial in China (CTR20240691) to determine its efficacy, safety, and optimal dosage in adults with biopsy-confirmed NASH. As a botanical formulation, it likely exerts its therapeutic effects through multi-target modulation of metabolic and inflammatory pathways associated with hepatic steatosis and fibrosis.

Brand names: Qinwei Jiaonang

Beyond the preview

Go deeper on Qinwei Jiaonang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qinwei Jiaonang.

Explore the full profile